Therapy Areas: Inflammatory Diseases
Lyra Therapeutics treats first patient in next stage LYR-220 trial
14 September 2022 -

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company, announced on Tuesday that it has treated its first patient in part two, the randomised stage, of the phase two BEACON clinical trial of LYR-220 in adult patients with chronic rhinosinusitis (CRS) with a prior sinus surgery.

The product is designed to deliver six months of continuous anti-inflammatory medication at a controlled rate to the sinonasal passages for CRS patients that continue to need treatment despite prior surgical treatment.

The Phase 2 BEACON trial, a parallel-group study, is to assess safety, tolerability, and pharmacokinetics of LYR-220 (7500-microg MF) matrix, over a 24-week period, in symptomatic adult CRS patients who have had a prior bilateral sinus surgery.

During the randomised Part two stage, one design of the product will be compared to control in around 40 patients. The firm expects to complete enrolment for the full Phase two BEACON trial around the end of 2022.



Related Headlines